This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Antisense Therapeutics, Ltd.
Drug Names(s): ISIS 107248, ATL1102, TV-1102
Description: ATL1102 inhibits cellular production of VLA-4, an adhesion molecule involved in cell-to-cell communication, especially in immune cells.
Antisense and Isis
In December 2001, Isis licensed ATL1102 to Antisense Therapeutics. Isis was responsible for completing the required preclinical studies for ATL1102 and for manufacturing the drug for human clinical trials at Antisenses expense. Antisense agreed to undertake the future clinical development and commercialization of the drug.
Antisense and Teva
In February 2008, Antisense (ANP) announced that it has entered an exclusive, world-wide license agreement with Teva Pharmaceutical to develop and commercialise ATL1102.
Under the terms of the agreement, ANP will receive an initial $US2m up-front payment. ANP also has the potential to receive payments related to the continued clinical development of ATL1102 for multiple sclerosis (MS) upon certain future development milestones, with more significant milestone payments for entry into the market, and sales targets in particular territories. The License includes potential milestone payments of up to...See full deal structure in Biomedtracker
Partners: Ionis Pharmaceuticals, Inc.
Additional information available to subscribers only: